Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensivedisease-small-cell lungcancer: Results from a randomized, double-blind, multicenter phase 2 trial

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 75-83

  Reck, M ^a   Bondarenko, I ^b   Luft, A ^c   Serwatowski, P ^d   Barlesi , F ^e   Chacko, R ^f   Sebastian, M ^g   Lu, H ^h   Cuillerot, J M ^h   Lynch, T J ⁱ  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Dnepropetrovsk City Clinical Hospital 4   (Ukraine)

^c Leningrad Regional Clinical Hospital   (Russian Federation)

^d Specjalistyczny Szpital im ^*  (Poland)

^e AIX MARSEILLE UNIVERSITY   (France)

^f CHRISTIAN MEDICAL COLLEGE   (India)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ YALE CANCER CENTER   (United States)

Author keywords

Combination therapy; First line treatment; Ipilimumab; Paclitaxel carboplatin; Randomized phase 2 trial; Small cell lungcancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CORTICOSTEROID; IPILIMUMAB; PACLITAXEL; PLACEBO;

ADULT; ALOPECIA; ANEMIA; APPETITE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; EXTENSIVE DISEASE SMALL CELL LUNG CANCER; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; HYPOPHYSITIS; INDUCTION CHEMOTHERAPY; LUNG SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 84871532643     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds213     Document Type: Article

References (47)

1. Puglisi M, Dolly S, Faria A et al. Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010; 102: 629-638.
2. Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 2001; 7: 437-447.
3. Oze I, Hotta K, Kiura K et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.
4. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
5. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
6. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA- 4 blockade. Science 1996; 271: 1734-1736.
7. Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2010; 2: 367-379.
8. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546.
9. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010; 25: 601-613.
10. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
11. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016.
12. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830.
13. Klein O, Ebert LM, Nicholaou T et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti- CTLA-4. Clin Cancer Res 2009; 15: 2507-2513.
14. Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol 2010; 37(Suppl 1): 48-53.
15. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-1815.
16. Ansell SM, Hurvitz SA, Koenig PA et al. Phase I study of ipilimumab, an anti- CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non- Hodgkin lymphoma. Clin Cancer Res 2009; 15: 6446-6453.
17. Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005-3010.
18. O'day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
19. Hodi FS, O'day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
20. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
21. Maddison P, Newsom-Davis J, Mills KR et al. Favourable prognosis in Lambert- Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353: 117-118.
22. Tani T, Tanaka K, Idezuka J et al. Regulatory T cells in praneoplastic neurological syndromes. J Neuroimmunol 2008; 196: 166-169.
23. Merritt RE, Mahtabifard A, Yamada RE et al. Cisplatin augments cytotoxic Tlymphocyte- mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1609-1617.
24. Tesniere A, Apetoh L, Ghiringhelli F et al. Immunogenic cancer cell death: a keylock paradigm. Curr Opin Immunol 2008; 20: 504-511.
25. Apetoh L, Tesniere A, Ghiringhelli F et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68: 4026-4030.
26. Correale P, Del Vecchio MT, La Placa M et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 2008; 31: 132-147.
27. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-1124.
28. Emens LA. Chemoimmunotherapy. Cancer J 2010; 16: 295-303.
29. Zitvogel L, Apetoh L, Ghiringhelli F et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
30. Masters G, Barreto L, Girit E et al. Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide or gemcitabine in murine models. J Immunother 2009; 32: 994 (Abstract).
31. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 2011; 3: 11-25.
32. Kosmidis P, Mylonakis N, Skarlos D et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000; 11: 799-805.
33. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
34. Gridelli C, Manzione L, Perrone F et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 2001; 84: 38-41.
35. Thomas P, Castelnau O, Paillotin D et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo- Cancerologie study. J Clin Oncol 2001; 19: 1320-1325.
36. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170: 4905-4913.
37. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878-887.
38. Lynch T, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multi-center phase 2 study. J Clin Oncol 2012; 30: 2046-2054.
39. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
40. Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
41. Taxol (paclitaxel). US Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb 2010.
42. Paraplatin (carboplatin). US Full Prescribing Information. Princeton, NJ: Bristol- Myers Squibb 2008.
43. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
44. Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
45. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
46. Braly P, Nicodemus CF, Chu C et al. The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009; 32: 54-65.
47. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti- CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507.